Compare XXI & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XXI | XENE |
|---|---|---|
| Founded | 2025 | 1996 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.4B |
| IPO Year | N/A | 2014 |
| Metric | XXI | XENE |
|---|---|---|
| Price | $9.27 | $40.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $54.09 |
| AVG Volume (30 Days) | ★ 1.4M | 984.3K |
| Earning Date | 01-01-0001 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.66 | $26.74 |
| 52 Week High | $59.75 | $46.60 |
| Indicator | XXI | XENE |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 39.60 |
| Support Level | N/A | $39.98 |
| Resistance Level | N/A | $42.14 |
| Average True Range (ATR) | 0.00 | 1.92 |
| MACD | 0.00 | -0.37 |
| Stochastic Oscillator | 0.00 | 1.41 |
Twenty One Capital Inc has no operation history.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.